Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Jan 11;378(2):199-200.
doi: 10.1056/NEJMc1714635.

Canakinumab for Atherosclerotic Disease

Robert A Harrington  1
Affiliations
Free article
Comment

Canakinumab for Atherosclerotic Disease

Robert A Harrington. N Engl J Med. .
Free article
No abstract available

PubMed Disclaimer

Comment on

  • Canakinumab for Atherosclerotic Disease.
    Derlin T, Bengel FM. Derlin T, et al. N Engl J Med. 2018 Jan 11;378(2):196-7. doi: 10.1056/NEJMc1714635. N Engl J Med. 2018. PMID: 29322754 No abstract available.
  • Canakinumab for Atherosclerotic Disease.
    Hjuler KF, Egeberg A. Hjuler KF, et al. N Engl J Med. 2018 Jan 11;378(2):197. doi: 10.1056/NEJMc1714635. N Engl J Med. 2018. PMID: 29322755 No abstract available.
  • Canakinumab for Atherosclerotic Disease.
    Rothman AM, Morton AC, Crossman DC; MRC-ILA Heart investigators. Rothman AM, et al. N Engl J Med. 2018 Jan 11;378(2):197-8. doi: 10.1056/NEJMc1714635. N Engl J Med. 2018. PMID: 29322756 No abstract available.
  • Canakinumab for Atherosclerotic Disease.
    O'Neill LA, Cooper MA. O'Neill LA, et al. N Engl J Med. 2018 Jan 11;378(2):198-9. doi: 10.1056/NEJMc1714635. N Engl J Med. 2018. PMID: 29322757 No abstract available.
  • Canakinumab for Atherosclerotic Disease.
    Nerlekar N, Harper RW. Nerlekar N, et al. N Engl J Med. 2018 Jan 11;378(2):199. doi: 10.1056/NEJMc1714635. N Engl J Med. 2018. PMID: 29322758 No abstract available.

LinkOut - more resources